Navigation Links
Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
Date:7/16/2008

the developed world.

Kuvan has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA). Kuvan has received seven years of market exclusivity in the United States. In November 2007, Merck Serono submitted a Marketing Authorization Application (MAA) to the EMEA for sapropterin dihydrochloride as an oral treatment for patients suffering from hyperphenylalaninemia (HPA) due to PKU or BH4 deficiency. If approved in the EU, it will receive 10 years of market exclusivity for this indication.

About PKU

PKU, a genetic disorder affecting approximately 50,000 diagnosed patients in the developed world, is caused by a deficiency of the enzyme phenylalanine hydroxylase. PAH is required for the metabolism of phenylalanine, an essential amino acid found in most protein-containing foods. If the active enzyme is not present in sufficient quantities, Phe accumulates to abnormally high levels in the blood and becomes toxic to the brain, resulting in a variety of complications including severe mental retardation and brain damage, mental illness, seizures, tremors, and limited cognitive ability. As a result of newborn screening efforts implemented in the 1960s and early 1970s, virtually all PKU patients under the age of 40 in developed countries have been diagnosed at birth. To learn more about PKU, please visit http://www.PKU.com. Information on this website is not incorporated by reference into this press release.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase)
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
2. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
3. Healthcare Announced That an Overwhelming Majority of its Shareholders Approved the NexGen Biofuels Transaction
4. Bystolic(TM), a Novel Beta Blocker, is Now Approved by the FDA for the Treatment of Hypertension
5. Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
6. EVICEL(TM) Fibrin Sealant (Human) Approved for General Hemostasis in Surgery
7. Clexane(R)/Lovenox(R) Approved in Japan
8. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
9. Center for Molecular Medicine Among First to Offer New FDA-Approved Test to Aid in Treatment of Prostate Cancer
10. Lucids VivaScope(R) Reflective Confocal Microscope Approved for Sale in China
11. Naglazyme Approved by Japanese Ministry of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... 28, 2014 /PRNewswire/ -   JOLT , a leading ... to join its growing portfolio of startups. Next-level tech ... Toronto,s JOLT accelerator, and Cohort four is ... Since its launch in July 2012, ...  $7.5M of financing. Now at 23 investments, JOLT,s portfolio ...
(Date:7/28/2014)... St Louis, MO (PRWEB) July 28, 2014 ... tools, software, and services that bring the power of ... for the inaugural Appistry Pipeline Challenge . ... Callum Bell, president of the National Center for Genome ... Children’s Mercy Hospitals and Clinics of Kansas City. Rounding ...
(Date:7/28/2014)... 2014 Research and Markets has announced ... 2014-2018" report to their offering. ... a technique used to determine the size of a particle ... crucial to analyze the size of particles as it can ... is performed to determine the behavior and nature of a ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Global Particle Size Analysis Market 2014-2018 2
... May 12 MedApps announced today, that,it has ... most innovative companies as,part of Dell,s 2008 Global ... MedApps Mobile Wireless Health Monitoring System helps connect,people ... Failure (CHF) and COPD, with their healthcare providers. ...
... Aton Pharma, Inc., a global,specialty pharmaceutical company, ... with Meizler Biopharma S/A to commercialize,CUPRIMINE(R) and SYPRINE(R) ... Meizler is working to obtain regulatory approval of ... products, and Aton is,committed to making these products ...
... China, May 12 /Xinhua-PRNewswire/ -- China Medicine,Corporation ... "the Company"),a leading distributor and developer of ... nutritional and,dietary-supplements, medical devices, and medical formulations ... reported solid financial results,for the first quarter ...
Cached Biology Technology:MedApps Selected as Dell-NFIB 2008 Business Excellence Award Finalist 2MedApps Selected as Dell-NFIB 2008 Business Excellence Award Finalist 3Aton Pharma Announces Distribution Partnership in Brazil 2China Medicine Announces Solid First Quarter 2008 Results 2China Medicine Announces Solid First Quarter 2008 Results 3China Medicine Announces Solid First Quarter 2008 Results 4China Medicine Announces Solid First Quarter 2008 Results 5China Medicine Announces Solid First Quarter 2008 Results 6China Medicine Announces Solid First Quarter 2008 Results 7China Medicine Announces Solid First Quarter 2008 Results 8China Medicine Announces Solid First Quarter 2008 Results 9China Medicine Announces Solid First Quarter 2008 Results 10
(Date:7/25/2014)... A study published online in the International ... novel approach to preventing cervical cancer based on findings ... after removal of a discrete population of cells in ... study that looked at squamocolumnar junction cells, or SCJ ... have been implicated as the origins of cervical cancer. ...
(Date:7/25/2014)... Prediabetes and Diabetes increasingly consume the healthcare ... immediate attention. , To address the ... impacting low-and middle-income countries, global leaders in ... research in diabetes prevention and development of ... important text. , This book on ...
(Date:7/25/2014)... Spina bifda (SB) is a complex congenital central ... incomplete closing of the neural tubes during the ... spasticity, urinary and fecal incontinence and neurocognitive retardation. ... their quality of life. Researchers at Ankara Physical ... investigate the functional performance in children with SB, ...
Breaking Biology News(10 mins):Clearing cells to prevent cervical cancer 2What constitutes an effective response to the global 'diabesity' tsunami? 2
... 15.11.2013/Gteborg, Kiel, Bremerhaven. Ocean acidification impairs digestion in marine ... journal Nature Climate Change . Researchers from Sweden ... sea urchins Strongylocentrotus droebachiensis . The results show ... water. Carbon dioxide (CO2) emissions do not only ...
... 2013)Provocative new research shows that the Plasmodium ... malaria in 2010, may be "rapidly evolving" to overcome the ... of Africans, scientists reported today at the annual meeting of ... In large swaths of sub-Saharan Africa, some ...
... international team of researchers led by the University of ... a new drug for possible use against heart disease, ... of Cardiovascular Sciences and Department of Biochemistry at the ... USA and Italy, have employed a new technique to ...
Cached Biology News:Ocean acidification: Hard to digest 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 2New research finds potential risk for millions in Africa believed resistant to vivax malaria 3New research finds potential risk for millions in Africa believed resistant to vivax malaria 4New technique for developing drugs to treat serious illnesses 2